Handelen Anixa Biosciences, Inc. - ANIX CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.23 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.024068% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.001846% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Belangrijkste statistieken
| Prev. Close* | 2.97 |
| Open* | 2.94 |
| 1-Jaarlijkse Verandering* | -1.67% |
| Dagelijks bereik* | 2.9 - 3.04 |
| 52 wekelijks bereik | 2.50-6.25 |
| Weekgemiddelde volume (10 dagen) | 68.87K |
| Gemiddeld volume (3 maanden) | 1.08M |
| Marktkapitalisatie | 134.83M |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 30.92M |
| Omzet | N/A |
| EPS | -0.40 |
| Dividend (opbrengst %) | N/A |
| Beta | 0.97 |
| Volgende inkomsten datum | N/A |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Jun 29, 2022 | 2.99 | 0.05 | 1.70% | 2.94 | 3.08 | 2.90 |
| Jun 28, 2022 | 2.97 | -0.04 | -1.33% | 3.01 | 3.14 | 2.95 |
| Jun 27, 2022 | 3.16 | 0.15 | 4.98% | 3.01 | 3.19 | 3.01 |
| Jun 24, 2022 | 3.04 | 0.07 | 2.36% | 2.97 | 3.12 | 2.97 |
| Jun 23, 2022 | 3.13 | 0.11 | 3.64% | 3.02 | 3.19 | 3.02 |
| Jun 22, 2022 | 3.18 | 0.21 | 7.07% | 2.97 | 3.18 | 2.97 |
| Jun 21, 2022 | 3.08 | 0.06 | 1.99% | 3.02 | 3.19 | 3.02 |
| Jun 17, 2022 | 3.00 | -0.16 | -5.06% | 3.16 | 3.16 | 2.96 |
| Jun 16, 2022 | 3.10 | 0.15 | 5.08% | 2.95 | 3.18 | 2.90 |
| Jun 15, 2022 | 3.08 | 0.29 | 10.39% | 2.79 | 3.15 | 2.79 |
| Jun 14, 2022 | 2.88 | -0.18 | -5.88% | 3.06 | 3.09 | 2.82 |
| Jun 13, 2022 | 3.07 | -0.18 | -5.54% | 3.25 | 3.31 | 3.04 |
| Jun 10, 2022 | 3.33 | -0.10 | -2.92% | 3.43 | 3.48 | 3.27 |
| Jun 9, 2022 | 3.48 | 0.07 | 2.05% | 3.41 | 3.68 | 3.41 |
| Jun 8, 2022 | 3.50 | 0.23 | 7.03% | 3.27 | 3.54 | 3.27 |
| Jun 7, 2022 | 3.38 | -0.49 | -12.66% | 3.87 | 3.91 | 3.30 |
| Jun 6, 2022 | 3.92 | -0.27 | -6.44% | 4.19 | 4.44 | 3.87 |
| Jun 3, 2022 | 3.94 | 0.16 | 4.23% | 3.78 | 3.96 | 3.61 |
| Jun 2, 2022 | 3.81 | 0.01 | 0.26% | 3.80 | 3.85 | 3.74 |
| Jun 1, 2022 | 3.69 | 0.18 | 5.13% | 3.51 | 3.70 | 3.37 |
Anixa Biosciences, Inc. Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| No events scheduled | ||
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale inkomsten | 0 | 0.5125 | 0 | 0.25 | 1.1125 |
| Inkomsten | 0 | 0.5125 | 0 | 0.25 | 1.1125 |
| Totale bedrijfskosten | 13.875 | 13.6482 | 9.9782 | 12.14 | 15.4016 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 7.172 | 7.0735 | 5.597 | 5.66283 | 6.91183 |
| Onderzoek & Ontwikkeling | 6.703 | 6.18969 | 4.38121 | 5.47343 | 6.81304 |
| Depreciation / Amortization | 0 | 0.41875 | 0.3253 | ||
| Ongebruikelijke uitgaven (inkomsten) | 0 | 0.385 | 0 | 0.585 | 1.35139 |
| Other Operating Expenses, Total | |||||
| Bedrijfsresultaat | -13.875 | -13.1357 | -9.9782 | -11.89 | -14.2891 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 0.104 | 0.00232 | 0.03392 | 0.07135 | 0.04597 |
| Netto inkomen voor belastingen | -13.771 | -13.1279 | -10.0924 | -11.8187 | -14.2431 |
| Netto inkomen na belastingen | -13.771 | -13.1279 | -10.0924 | -11.8187 | -14.2431 |
| Netto inkomen voor extra. Posten | -13.595 | -12.9544 | -10.0184 | -11.647 | -13.996 |
| Netto inkomen | -13.595 | -12.9544 | -10.0184 | -11.647 | -13.996 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -13.595 | -12.9544 | -10.0184 | -11.647 | -13.996 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -13.595 | -12.9544 | -10.0184 | -11.647 | -13.996 |
| Verwaterd Netto Inkomen | -13.595 | -12.9544 | -10.0184 | -11.647 | -13.996 |
| Verwaterd Gewogen Gemiddelde Aandelen | 30.374 | 28.5789 | 22.229 | 19.7898 | 17.6243 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.44759 | -0.45329 | -0.45069 | -0.58854 | -0.79413 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Verwaterde Genormaliseerde Winst per Aandeel | -0.44759 | -0.44 | -0.44403 | -0.55898 | -0.71745 |
| Total Adjustments to Net Income | 0 | ||||
| Minderheidsbelang | 0.176 | 0.17352 | 0.07401 | 0.1716 | 0.24706 |
| Gain (Loss) on Sale of Assets | 0 | 0.00545 | -0.14808 |
| Oct 2022 | Jul 2022 | Apr 2022 | Jan 2022 | Oct 2021 | |
|---|---|---|---|---|---|
| Totale inkomsten | 0 | 0 | 0 | 0 | 0 |
| Inkomsten | 0 | 0 | 0 | 0 | 0 |
| Totale bedrijfskosten | 3.609 | 2.797 | 3.589 | 3.88 | 4.07704 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 1.924 | 1.352 | 1.854 | 2.042 | 1.9038 |
| Onderzoek & Ontwikkeling | 1.685 | 1.445 | 1.735 | 1.838 | 2.17324 |
| Ongebruikelijke uitgaven (inkomsten) | 0 | 0 | 0 | 0 | 0 |
| Bedrijfsresultaat | -3.609 | -2.797 | -3.589 | -3.88 | -4.07704 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 0.08 | 0.022 | 0.001 | 0.001 | 0.00055 |
| Netto inkomen voor belastingen | -3.529 | -2.775 | -3.588 | -3.879 | -4.07105 |
| Netto inkomen na belastingen | -3.529 | -2.775 | -3.588 | -3.879 | -4.07105 |
| Minderheidsbelang | 0.053 | 0.029 | 0.044 | 0.05 | 0.05778 |
| Netto inkomen voor extra. Posten | -3.476 | -2.746 | -3.544 | -3.829 | -4.01327 |
| Netto inkomen | -3.476 | -2.746 | -3.544 | -3.829 | -4.01327 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -3.476 | -2.746 | -3.544 | -3.829 | -4.01327 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -3.476 | -2.746 | -3.544 | -3.829 | -4.01327 |
| Verwaterd Netto Inkomen | -3.476 | -2.746 | -3.544 | -3.829 | -4.01327 |
| Verwaterd Gewogen Gemiddelde Aandelen | 30.764 | 30.451 | 30.152 | 30.125 | 30.0451 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.11299 | -0.09018 | -0.11754 | -0.1271 | -0.13357 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| Verwaterde Genormaliseerde Winst per Aandeel | -0.11299 | -0.09018 | -0.11754 | -0.1271 | -0.13376 |
| Gain (Loss) on Sale of Assets | 0 | 0.00545 |
- Jaarlijks
- Per kwartaal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 36.0034 | 9.36862 | 6.09312 | 5.53837 | 7.01394 |
| Geldmiddelen en kortetermijnbeleggingen | 35.7279 | 9.05706 | 5.84163 | 5.05589 | 6.83937 |
| Geldmiddelen & Equivalenten | 29.1283 | 6.41706 | 3.49163 | 3.05589 | 3.33937 |
| Korte Termijn Investeringen | 6.5996 | 2.64 | 2.35 | 2 | 3.5 |
| Prepaid Expenses | 0.27556 | 0.30933 | 0.18497 | 0.17549 | 0.17457 |
| Total Assets | 36.2574 | 9.45296 | 6.29369 | 6.44854 | 8.81242 |
| Property/Plant/Equipment, Total - Net | 0.25396 | 0.05434 | 0.20057 | 0.07267 | 0.0527 |
| Property/Plant/Equipment, Total - Gross | 0 | 0.29558 | 0.12647 | 0.08843 | |
| Accumulated Depreciation, Total | 0 | -0.09502 | -0.0538 | -0.03573 | |
| Intangibles, Net | 0 | 0.8375 | 1.74578 | ||
| Total Current Liabilities | 1.27053 | 1.18859 | 1.48132 | 1.26511 | 0.88949 |
| Accounts Payable | 0.1362 | 0.23237 | 0.58582 | 0.58201 | 0.48032 |
| Accrued Expenses | 1.13433 | 0.95622 | 0.8955 | 0.6831 | 0.40917 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | |||||
| Total Liabilities | 0.8201 | 0.69161 | 1.05834 | 1.01373 | 0.88949 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.22008 | 0 | |||
| Total Equity | 35.4373 | 8.76136 | 5.23535 | 5.43481 | 7.92292 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.30051 | 0.24249 | 0.20332 | 0.18909 | 0.16603 |
| Additional Paid-In Capital | 239.927 | 200.354 | 186.849 | 175.416 | 163.931 |
| Retained Earnings (Accumulated Deficit) | -204.79 | -191.836 | -181.817 | -170.17 | -156.174 |
| Total Liabilities & Shareholders’ Equity | 36.2574 | 9.45296 | 6.29369 | 6.44854 | 8.81242 |
| Total Common Shares Outstanding | 30.0509 | 24.2487 | 20.3318 | 18.9086 | 16.6028 |
| Total Preferred Shares Outstanding | 0 | 0 | 0 | 0 | 0 |
| Totale Vorderingen, Netto | 0.00223 | 0.06653 | 0.30699 | ||
| Accounts Receivable - Trade, Net | 0.00223 | 0.06653 | 0.30699 | ||
| Minority Interest | -0.67051 | -0.49698 | -0.42298 | -0.25138 | |
| Other Long Term Assets, Total | 0 | 0.03 |
| Apr 2022 | Jan 2022 | Oct 2021 | Jul 2021 | Apr 2021 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 32.563 | 34.994 | 36.0034 | 37.052 | 38.472 |
| Geldmiddelen en kortetermijnbeleggingen | 32.231 | 34.53 | 35.7279 | 36.622 | 38.1027 |
| Geldmiddelen & Equivalenten | 27.732 | 29.781 | 29.1283 | 27.2222 | 27.7034 |
| Korte Termijn Investeringen | 4.499 | 4.749 | 6.5996 | 9.39978 | 10.3993 |
| Prepaid Expenses | 0.332 | 0.464 | 0.27556 | 0.43001 | 0.36921 |
| Total Assets | 32.797 | 35.238 | 36.2574 | 37.0624 | 38.4975 |
| Property/Plant/Equipment, Total - Net | 0.234 | 0.244 | 0.25396 | 0.01041 | 0.02557 |
| Other Long Term Assets, Total | 0 | 0 | 0 | ||
| Total Current Liabilities | 1.189 | 1.787 | 1.27053 | 1.20802 | 1.44287 |
| Accounts Payable | 0.093 | 0.504 | 0.1362 | 0.20773 | 0.43801 |
| Accrued Expenses | 1.096 | 1.283 | 1.13433 | 1.00029 | 1.00486 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 0.626 | 1.275 | 0.8201 | 0.5953 | 0.88376 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -0.765 | -0.721 | -0.67051 | -0.61273 | -0.55911 |
| Total Equity | 32.171 | 33.963 | 35.4373 | 36.4671 | 37.6138 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.302 | 0.301 | 0.30051 | 0.2995 | 0.3145 |
| Additional Paid-In Capital | 244.032 | 242.281 | 239.927 | 236.944 | 233.742 |
| Retained Earnings (Accumulated Deficit) | -212.163 | -208.619 | -204.79 | -200.777 | -196.443 |
| Total Liabilities & Shareholders’ Equity | 32.797 | 35.238 | 36.2574 | 37.0624 | 38.4975 |
| Total Common Shares Outstanding | 30.1547 | 30.1323 | 30.0509 | 29.9499 | 31.4499 |
| Other Liabilities, Total | 0.202 | 0.209 | 0.22008 | ||
| Total Preferred Shares Outstanding | 0 |
- Jaarlijks
- Per kwartaal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -13.1279 | -10.0924 | -11.8187 | -14.2431 | -5.00899 |
| Geldmiddelen uit Operationele Activiteiten | -4.93688 | -6.17567 | -4.74143 | -4.2734 | -3.79671 |
| Geldmiddelen uit Operationele Activiteiten | 0 | 0.03828 | 0.04756 | 0.01844 | 0.04322 |
| Amortization | 0 | 0.41875 | 0.3253 | 0.3253 | |
| Niet-Geldelijke Posten | 8.1125 | 4.33743 | 6.1325 | 9.55825 | 0.43553 |
| Veranderingen in het Operationeel Kapitaal | 0.07855 | -0.45901 | 0.47842 | 0.0677 | 0.40824 |
| Geldmiddelen uit Investeringsactiviteiten | -3.91768 | -0.30579 | -0.52546 | 1.4616 | -2.73519 |
| Kapitaaluitgaven | 0 | -0.01579 | -0.17546 | -0.0384 | -0.03019 |
| Overige Cash Flow investeringsposten, Totaal | -3.91768 | -0.29 | -0.35 | 1.5 | -2.705 |
| Geldmiddelen uit Financieringsactiviteiten | 31.5658 | 9.4069 | 5.70262 | 2.52832 | 7.38295 |
| Financiering van Cash Flow Posten | 0.01403 | 0 | |||
| Uitgifte (Aflossing) van aandelen, netto | 31.5658 | 9.4069 | 5.68858 | 2.52832 | 10.3829 |
| Nettowijziging in Geldmiddelen | 22.7112 | 2.92544 | 0.43574 | -0.28348 | 0.85105 |
| Contant Betaalde Rente | 0.00182 | 0.03989 | 0 | 0.27243 | |
| Uitgifte (Aflossing) van Schulden, Netto | 0 | -3 |
| Apr 2022 | Jan 2022 | Oct 2021 | Jul 2021 | Apr 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -7.467 | -3.879 | -13.1279 | -9.05688 | -4.66927 |
| Cash From Operating Activities | -3.503 | -1.197 | -4.93688 | -3.89271 | -2.41195 |
| Cash From Operating Activities | 0 | 0 | 0 | ||
| Non-Cash Items | 4.12 | 2.364 | 8.1125 | 5.26318 | 2.06069 |
| Cash Interest Paid | 2 | 1 | 0.00182 | 0.00168 | 0.0014 |
| Changes in Working Capital | -0.156 | 0.318 | 0.07855 | -0.09901 | 0.19663 |
| Cash From Investing Activities | 2.1 | 1.85 | -3.91768 | -6.72434 | -7.72385 |
| Capital Expenditures | 0 | 0 | 0 | ||
| Other Investing Cash Flow Items, Total | 2.1 | 1.85 | -3.91768 | -6.72434 | -7.72385 |
| Cash From Financing Activities | 0.007 | 0 | 31.5658 | 31.4222 | 31.4222 |
| Financing Cash Flow Items | 0 | -2.54893 | -2.54893 | ||
| Issuance (Retirement) of Stock, Net | 0.007 | 0 | 31.5658 | 33.9711 | 33.9711 |
| Net Change in Cash | -1.396 | 0.653 | 22.7112 | 20.8051 | 21.2864 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.2268 | 1307142 | 7144 | 2022-12-31 | LOW |
| Titterton (Lewis H Jr) | Individual Investor | 2.5031 | 774070 | 0 | 2023-01-17 | LOW |
| UBS Financial Services, Inc. | Investment Advisor | 2.0131 | 622544 | 853 | 2022-12-31 | LOW |
| Kumar (Amit) | Individual Investor | 1.4943 | 462100 | 0 | 2023-01-17 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.9353 | 289238 | -2985 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.887 | 274289 | 3626 | 2022-12-31 | LOW |
| Long Focus Capital Management LLC | Hedge Fund | 0.5358 | 165701 | 0 | 2022-12-31 | MED |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3302 | 102100 | 0 | 2022-12-31 | LOW |
| Baskies (Arnold M) | Individual Investor | 0.3234 | 100000 | 0 | 2023-01-17 | LOW |
| Susquehanna International Group, LLP | Investment Advisor | 0.2297 | 71023 | 31115 | 2022-12-31 | MED |
| Raymond James & Associates, Inc. | Research Firm | 0.185 | 57217 | -3629 | 2022-12-31 | LOW |
| Newton Investment Management North America, LLC | Investment Advisor | 0.179 | 55350 | 0 | 2022-12-31 | MED |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1777 | 54948 | 0 | 2022-12-31 | LOW |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.1582 | 48925 | -714 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.1549 | 47900 | -9300 | 2022-12-31 | HIGH |
| Citadel Advisors LLC | Hedge Fund | 0.1536 | 47506 | 27896 | 2022-12-31 | HIGH |
| Gottschalk (Emily) | Individual Investor | 0.1477 | 45665 | 0 | 2023-01-17 | LOW |
| BNY Mellon Asset Management | Investment Advisor | 0.1367 | 42268 | -238 | 2022-12-31 | LOW |
| Cambridge Investment Research Advisors, Inc. | Investment Advisor | 0.1297 | 40100 | 25100 | 2022-12-31 | LOW |
| Corecap Advisors Inc | Investment Advisor/Hedge Fund | 0.1171 | 36209 | -1177 | 2022-12-31 | MED |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group500K+
Handelaren
92K+
Actieve klanten per maand
$53M+
Maandelijks beleggingsvolume
$30M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Anixa Biosciences, Inc. Company profile
Over Anixa Biosciences, Inc.
Anixa Biosciences, Inc. is een biotechnologiebedrijf. De Vennootschap ontwikkelt therapieën en vaccins die gericht zijn op oncologie en infectieziekten. De Vennootschap ontwikkelt chimere endocriene receptor T-celtechnologie, een chimere antigen receptor T-cel (CAR-T) technologie gericht op de behandeling van eierstokkanker, en antivirale kandidaat-geneesmiddelen voor de behandeling van COVID-19 gericht op het remmen van bepaalde virale eiwitfuncties van het virus. Het ontwikkelt ook een vaccin tegen triple negatieve borstkanker (TNBC), de dodelijke vorm van borstkanker, en een vaccin tegen eierstokkanker. Zijn CAR-T-technologie kan worden gebruikt als behandeling tegen meerdere vaste tumortypes. De segmenten van het bedrijf omvatten CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, Cancer Diagnostics activiteiten, en Patent Licensing activiteiten. Haar dochteronderneming Certainty Therapeutics, Inc. (Certainty), ontwikkelt geneesmiddelen voor immuno-therapie tegen kanker.
| Industry: | Biotechnology & Medical Research (NEC) |
3150 Almaden Expy Ste 250
SAN JOSE
CALIFORNIA 95118
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 500.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen